Delaware judge ap­proves Mallinck­rodt's sec­ond bank­rupt­cy plan since 2020

A Delaware fed­er­al bank­rupt­cy judge has ap­proved Mallinck­rodt’s re­or­ga­ni­za­tion plan, elim­i­nat­ing near­ly $2 bil­lion in debt and al­low­ing the com­pa­ny to ex­it its sec­ond bank­rupt­cy in three years.

The 150-plus-year-old Irish drug­mak­er first filed for bank­rupt­cy in 2020 un­der a moun­tain of opi­oid law­suits and lit­i­ga­tion around its top-sell­ing mul­ti­ple scle­ro­sis drug Ac­thar Gel. It made an ini­tial $450 mil­lion pay­ment to­ward an opi­oid set­tle­ment when it emerged from bank­rupt­cy in 2022, and will make an­oth­er pay­ment of $250 mil­lion as part of its lat­est re­struc­tur­ing plan.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER